Furthermore, dual-agent approaches combining PD-1 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors show potential, as seen in CheckMate-142, which reported a 55% ORR in dMMR/MSI metastatic colorectal cancer (65). This evidence concerns the gene CTLA4 and metastatic colorectal cancer.